Volume : 13, Issue : 03, March – 2026
Title:
RECENT ADVANCES IN TARGETED DRUG DELIVERY SYSTEMS FOR CANCER THERAPY: FORMULATION STRATEGIES, PHARMACOLOGICAL MECHANISMS AND CLINICAL APPLICATIONS
Authors :
Aishwarya Nanasaheb Babar, Amruta Shashikant Madane, Rutuja Rajaram Katare, Mujawar suhana salim*, Dr. Rahul ishwara jadhav
Abstract :
Cancer continues to represent a major global health burden, necessitating the development of more precise and effective therapeutic strategies. Conventional chemotherapy, although widely used, is associated with significant limitations including systemic toxicity, poor selectivity, unfavorable pharmacokinetics, and the emergence of multidrug resistance. Targeted drug delivery systems (TDDS) have emerged as a transformative approach to address these shortcomings by enhancing tumor-specific drug accumulation while minimizing off-target effects.
This review comprehensively discusses recent advances in targeted drug delivery systems for cancer therapy, focusing on formulation strategies, pharmacological mechanisms, and clinical applications. Various nanocarrier platforms—including lipid-based systems, polymeric nanoparticles, inorganic nanomaterials, and biomimetic carriers—are critically analyzed in terms of design principles, drug loading capacity, surface functionalization, and targeting efficiency. Mechanistic insights into cellular uptake pathways, intracellular trafficking, resistance modulation, and tumor microenvironment responsiveness are elaborated to highlight their contribution to improved therapeutic outcomes.
Clinically approved targeted formulations such as liposomal chemotherapeutics, albumin-bound nanoparticles, and antibody–drug conjugates demonstrate the translational potential of nanomedicine in oncology. Despite these advancements, challenges including tumor heterogeneity, variability of the enhanced permeability and retention effect in humans, immunogenicity, large-scale manufacturing constraints, and regulatory complexities remain significant barriers.
Future perspectives emphasize personalized nanomedicine, artificial intelligence-assisted nanoparticle design, combination therapeutic approaches, and theranostic systems integrating diagnosis and therapy. Continued interdisciplinary innovation and translational research are essential to optimize targeted drug delivery platforms and advance precision oncology.
KEYWORDS
Targeted drug delivery systems; Cancer therapy; Nanomedicine; Liposomes; Polymeric nanoparticles; Antibody–drug conjugates; Tumor microenvironment; Enhanced permeability and retention effect; Stimuli-responsive systems; Personalized nanomedicine
Cite This Article:
Please cite this article in press Mujawar suhana salim et al., Recent Advances In Targeted Drug Delivery Systems For Cancer Therapy: Formulation Strategies, Pharmacological Mechanisms And Clinical Applications., Indo Am. J. P. Sci, 2026; 13(03).
REFERENCES:
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide. CA Cancer J Clin. 2021;71(3):209–249.
2. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–3030.
3. Chabner BA, Roberts TG. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65–72.
4. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–627.
5. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726.
6. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect. J Control Release. 2000;65(1–2):271–284.
7. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels. Adv Drug Deliv Rev. 2011;63(3):136–151.
8. Torchilin VP. Multifunctional nanocarriers. Nat Rev Drug Discov. 2014;13(11):813–827.
9. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform. Nat Nanotechnol. 2007;2(12):751–760.
10. Allen TM, Cullis PR. Liposomal drug delivery systems. Adv Drug Deliv Rev. 2013;65(1):36–48.
11. Immordino ML, Dosio F, Cattel L. Stealth liposomes. Int J Nanomedicine. 2006;1(3):297–315.
12. Barenholz Y. Doxil®—The first FDA-approved nano-drug. J Control Release. 2012;160(2):117–134.
13. Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. J Clin Oncol. 2005;23(31):7794–7803.
14. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes. Pharmacol Rev. 1999;51(4):691–743.
15. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6(9):688–701.
16. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA nanoparticles. J Control Release. 2012;161(2):505–522.
17. Koo H, Huh MS, Sun IC, Yuk SH, Choi K, Kim K, et al. In vivo tumor targeting of nanoparticles. Acc Chem Res. 2011;44(10):1018–1028.
18. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–198.
19. Bae YH, Park K. Targeted drug delivery to tumors. J Control Release. 2011;153(3):198–205.
20. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers. Nat Mater. 2013;12(11):991–1003.
21. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine—Challenge and perspectives. Angew Chem Int Ed. 2009;48(5):872–897.
22. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles. Chem Soc Rev. 2012;41(7):2971–3010.
23. Sanna V, Sechi M. Nanoparticle therapeutics. Int J Nanomedicine. 2012;7:1731–1746.
24. Ferrari M. Cancer nanotechnology. Nat Rev Cancer. 2005;5(3):161–171.
25. Mitragotri S, Anderson DG, Chen X, Chow EK, Ho D, Kabanov AV, et al. Accelerating nanomedicine translation. ACS Nano. 2015;9(7):6644–6654.
26. Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy. J Control Release. 2015;200:138–157.
27. Jain RK. Delivery of molecular medicine to solid tumors. Science. 1996;271(5252):1079–1080.
28. Rasve V, Chakraborty AK, Jain SK, Vengurlekar S. Study of phytochemical profiling and in vitro antioxidant properties of ethanolic extract of Clematis triloba. Eur Chem Bull. 2022;11(12):2658–2677. doi:10.53555/ecb/2022.11.12.2162022.
29. Rasve VR, Paithankar VV, Shirsat MK, Dhobale AV. Evaluation of antiulcer activity of Aconitum heterophyllum in experimental animals. World J Pharm Pharm Sci. 2018;7(2):819–839.
30. Stylianopoulos T. EPR-effect-based drug delivery. J Control Release. 2013;172(3):779–786.
31. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine. Nat Rev Cancer. 2017;17(1):20–37.
32. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology. Adv Drug Deliv Rev. 2014;66:2–25.
33. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody-targeted liposomes. Cancer Res. 2006;66(13):6732–6740.
34. Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for next-generation ADCs. Nat Rev Drug Discov. 2017;16(5):315–337.
35. Sievers EL, Senter PD. Antibody–drug conjugates. Annu Rev Med. 2013;64:15–29.
36. Lambert JM, Morris CQ. Antibody–drug conjugates (ADCs). Adv Ther. 2017;34(5):1015–1035.
37. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines. Pharm Res. 2016;33(10):2373–2387.
38. Petros RA, DeSimone JM. Strategies in the design of nanoparticles. Nat Rev Drug Discov. 2010;9(8):615–627.
39. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design. Nat Biotechnol. 2015;33(9):941–951.
40. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size. Annu Rev Biomed Eng. 2012;14:1–16.
41. Wang Y, Zhang L, Guo S. Stimuli-responsive nanocarriers. Small. 2015;11(14):1640–1651.
42. Ruan S, He Q, Gao H. Matrix metalloproteinase-responsive systems. Nano Today. 2015;10(6):699–713.
43. Li J, Mooney DJ. Designing hydrogels for controlled release. Nat Rev Mater. 2016;1:16071.
44. Torchilin VP. Recent advances with liposomes. Nat Rev Drug Discov. 2005;4(2):145–160.
45. Rasve V, Chakraborty AK, Jain SK, Vengurlekar S. Comparative evaluation of antidiabetic activity of ethanolic leaves extract of Clematis triloba and its SMEDDS formulation in streptozotocin-induced diabetic rats. J Popul Ther Clin Pharmacol. 2022;29(4):959–971. doi:10.53555/jptcp.v29i04.2360.
46. Sanna V, Pala N, Sechi M. Targeted therapy using nanoparticles. Future Med Chem. 2014;6(10):1093–1116.
47. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653–664.
48. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles. Science. 2012;338(6109):903–910.
49. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery efficiency. Nat Rev Mater. 2016;1:16014.
50. Shi Y, van der Meel R, Theek B, Oude Blenke E, Pieters EH, Fens MH, et al. Complete regression of xenograft tumors. ACS Nano. 2015;9(4):3740–3752.
51. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;1(1):10–29.
52. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine. Adv Drug Deliv Rev. 2017;108:25–38.
53. Bae YH, Park K. Targeted drug delivery to tumors: Myths and reality. J Control Release. 2011;153(3):198–205.
54. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs. Clin Cancer Res. 2002;8(3):878–884.
55. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16–20.
56. Zhao Y, Alakhova DY, Kabanov AV. Can nanomedicines kill cancer stem cells?Adv Drug Deliv Rev. 2013;65(13–14):1763–1783.
57. Chen F, Ehlerding EB, Cai W. Theranostic nanoparticles. J Nucl Med. 2014;55(12):1919–1922.
58. Kelkar SS, Reineke TM. Theranostics in nanomedicine. Bioconjug Chem. 2011;22(10):1879–1903.